San Francisco, April 21, 2026 — Sleuth Insights, Inc., an AI decision platform for pharmaceutical and biotech intelligence teams, today announced its launch from stealth with $8 million in seed funding led by Bison Ventures.
Biopharma's highest-stakes decisions — which assets to acquire, which markets to enter, where to compete — depend on teams synthesizing vast amounts of external data under time pressure. Strategy groups, BD teams, and competitive intelligence analysts do this work across fragmented databases, manual processes, and third-party consultants. The result: strategic analyses that take eight weeks, and billion-dollar calls made on incomplete information.
Sleuth accelerates the work of the teams behind running acquisition diligence, setting commercial strategy, and tracking competitor pipelines and market dynamics. Across these functions, the core challenge is the same: synthesizing vast amounts of external data from disparate sources into actionable insights under time pressure.
"I spent my career in life sciences banking, investing, and operations, and the pattern was the same everywhere: teams spending months to build conviction on decisions worth billions, working from incomplete and disconnected information," said Andrew Pannu, Founder and CEO of Sleuth Insights. “We built Sleuth to give those teams a fundamentally different starting point: the full picture of the biopharma landscape, structured around their questions, with defensible decisions at the pace the market now demands.”
Sleuth provides an end-to-end platform that takes a strategic question through to an executive-ready analysis — aggregating clinical, competitive, and market data from a curated knowledge base of hundreds of millions of biopharma data points; running domain-specific analysis; and producing traceable, presentation-ready output. Analyses that previously took weeks are compressed to hours.
Sleuth is already in use at dozens of biopharma companies including Daiichi Sankyo, serving teams across strategy, BD, and competitive intelligence functions.
With the pharmaceutical industry spending more than $100 billion annually on acquisitions and more than $200 billion in branded drug revenue facing patent expiration by 2030, the pressure on intelligence teams to evaluate more opportunities, faster, is accelerating.
"The most consequential decisions in biopharma are deciding how to prioritize the pipeline, which assets to acquire, and where to compete. We believe these are the areas where AI will bring the most immediate benefits to the effort to cure disease,” said Caleb Appleton, Partner at Bison Ventures, who led the investment and joined Sleuth’s board. “Sleuth finally built the decision infrastructure this industry has been missing — domain-specific AI that pharma and biotech companies already trust for consequential analysis. That combination of technical depth and early enterprise traction is rare at the seed stage.”
Sleuth will use the new funding to expand its engineering and data science teams, deepen its biopharma knowledge base, and broaden platform capabilities across intelligence workflows in pharma and biotech.
About Sleuth Insights, Inc.
Sleuth is an AI decision platform for pharma and biotech intelligence teams. The platform delivers end-to-end analysis — from data aggregation through executive-ready output — enabling strategy, business development, and competitive intelligence teams to make faster, higher-quality decisions. Sleuth serves pharmaceutical and biotech companies and is backed by Bison Ventures. For more information, visit sleuthinsights.com.
